Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: Renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin (Clinical Science (2018) 132:4 (489–507) DOI: 10.1042/CS20180031);The role of renal dipeptidyl peptidase-4 in kidney disease: Renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin

Clinical Science

Volumn 132, Issue 4, 2018, Pages 489-507

  Kanasaki, Keizo ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN;

ANIMAL; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN;

EID: 85045643924     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20180031_COR     Document Type: Erratum

References (158)

1. International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn, International Diabetes Federation, Brussels, Belgium, http://www.diabetesatlas.org/resources/2017-atlas.html
2. Centers for Disease Control and Prevention (2017) National Diabetes Statistics Report, 2017, Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, Atlanta, GA, https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
3. Thomas, M.C., Cooper, M.E. and Zimmet, P. (2016) Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12, 73-81, https://doi.org/10.1038/nrneph.2015.173
4. National Kidney Foundation (2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am. J. Kidney Dis. 60, 850-886, https://doi.org/10.1053/j.ajkd.2012.07.005
5. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). . Lancet 352, 837-853, https://doi.org/10.1016/S0140-6736(98)07019-6
6. Zoungas, S., Arima, H., Gerstein, H.C., Holman, R.R., Woodward, M., Reaven, P. et al. (2017) Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 5, 431-437, https://doi.org/10.1016/S2213-8587(17)30104-3
7. Ismail-Beigi, F., Craven, T., Banerji, M.A., Basile, J., Calles, J., Cohen, R.M. et al. (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430, https://doi.org/10.1016/S0140-6736(10)60576-4
8. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M. et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572, https://doi.org/10.1056/NEJMoa0802987
9. Perkovic, V., Heerspink, H.L., Chalmers, J., Woodward, M., Jun, M., Li, Q. et al. (2013) Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517-523, https://doi.org/10.1038/ki.2012.401
10. Wong, M.G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M.E. et al. (2016) Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39, 694-700, https://doi.org/10.2337/dc15-2322
11. Rao Kondapally Seshasai, S., Kaptoge, S., Thompson, A., Di Angelantonio, E., Gao, P., Sarwar, N. et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364, 829-841, https://doi.org/10.1056/NEJMoa1008862
12. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B. et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860, https://doi.org/10.1056/NEJMoa011303
13. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869, https://doi.org/10.1056/NEJMoa011161
14. de Zeeuw, D. and Heerspink, H.J. (2016) Unmet need in diabetic nephropathy: failed drugs or trials? Lancet Diabetes Endocrinol. 4, 638-640, https://doi.org/10.1016/S2213-8587(16)30045-6
15. Wanner, C., Inzucchi, S.E. and Zinman, B. (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323-334, https://doi.org/10.1056/NEJMoa1515920
16. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N. et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644-657, https://doi.org/10.1056/NEJMoa1611925
17. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M. et al. (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140-149, https://doi.org/10.2337/dc14-2441
18. Shi, S., Koya, D. and Kanasaki, K. (2016) Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair 9, 1, https://doi.org/10.1186/s13069-016-0038-0
19. Takagaki, Y., Koya, D. and Kanasaki, K. (2017) Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects. Curr. Opin. Nephrol. Hypertens. 26, 56-66, https://doi.org/10.1097/MNH.0000000000000291
20. Golightly, L.K., Drayna, C.C. and McDermott, M.T. (2012) Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin. Pharmacokinet. 51, 501-514, https://doi.org/10.1007/BF03261927
21. Blech, S., Ludwig-Schwellinger, E., Grafe-Mody, E.U., Withopf, B. and Wagner, K. (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos. 38, 667-678, https://doi.org/10.1124/dmd.109.031476
22. Graefe-Mody, U., Friedrich, C., Port, A., Ring, A., Retlich, S., Heise, T. et al. (2011) Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes. Metab. 13, 939-946, https://doi.org/10.1111/j.1463-1326.2011.01458.x
23. (2016) Tradjenta (linagliptin) prescribing information. Eli Lilly and Company, Indianapolis, IN, https://www.accessdata.fda.gov/drugsatfda docs/label/2017/201280s016lbl.pdf
24. Merck & Co., Inc. (2017) Januvia (sitagliptin) Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, https://www.accessdata.fda.gov/drugsatfda docs/label/2017/021995s038lbl.pdf
25. AstraZeneca Pharmaceuticals LP (2017) Onglyza (saxagliptin) Prescribing Information, AstraZeneca Pharmaceuticals LP, Willmington, DE, https://www.accessdata.fda.gov/drugsatfda docs/label/2017/022350s018lbl.pdf
26. Takeda Pharmaceuticals America, Inc. (2016) Nesina (alogliptin) prescribing information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, https://www.accessdata.fda.gov/drugsatfda docs/label/2016/022271s011lbl.pdf
27. Novartis Europharm Limited (2014) Galvus (vildagliptin) Summary of Product Characteristics, Novartis Europharm Limited, Camberely, United Kingdom, http://www.ema.europa.eu/docs/en GB/document library/EPAR-Product Information/human/000771/WC500020327.pdf
28. Lambeir, A.M., Durinx, C., Scharpe, S. and De Meester, I. (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294, https://doi.org/10.1080/713609354
29. Engel, M., Hoffmann, T., Wagner, L., Wermann, M., Heiser, U., Kiefersauer, R. et al. (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U.S.A. 100, 5063-5068, https://doi.org/10.1073/pnas.0230620100
30. Chien, C.H., Huang, L.H., Chou, C.Y., Chen, Y.S., Han, Y.S., Chang, G.G. et al. (2004) One site mutation disrupts dimer formation in human DPP-IV proteins. J. Biol. Chem. 279, 52338-52345, https://doi.org/10.1074/jbc.M406185200
31. Klemann, C., Wagner, L., Stephan, M. and von Horsten, S. (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin. Exp. Immunol. 185, 1-21, https://doi.org/10.1111/cei.12781
32. Mulvihill, E.E. and Drucker, D.J. (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992-1019, https://doi.org/10.1210/er.2014-1035
33. Wang, Z., Grigo, C., Steinbeck, J., von Horsten, S., Amann, K. and Daniel, C. (2014) Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 57, 109-117, https://doi.org/10.1016/j.peptides.2014.05.006
34. Hopsu-Havu, V.K. and Glenner, G.G. (1966) A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7, 197-201, https://doi.org/10.1007/BF00577838
35. Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A.M. and De Meester, I. (2015) The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front. Immunol. 6, 387, https://doi.org/10.3389/fimmu.2015.00387
36. Vanderheyden, M., Bartunek, J., Goethals, M., Verstreken, S., Lambeir, A.M., De Meester, I. et al. (2009) Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin. Chem. Lab. Med. 47, 248-252, https://doi.org/10.1515/CCLM.2009.065
37. Andersen, E.S., Deacon, C.F. and Holst, J.J. (2017) Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes. Metab. 20, 34-41, https://doi.org/10.1111/dom.13018
38. Mentlein, R. (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24, https://doi.org/10.1016/S0167-0115(99)00089-0
39. Kettmann, U., Humbel, B. and Holzhausen, H.J. (1992) Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem. 92, 225-227, https://doi.org/10.1016/S0065-1281(11)80085-1
40. Nargis, T., Kumar, K., Ghosh, A.R., Sharma, A., Rudra, D., Sen, D. et al. (2017) KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Mol. Metab. 6, 1529-1539, https://doi.org/10.1016/j.molmet.2017.09.004
41. Hartel, S., Gossrau, R., Hanski, C. and Reutter, W. (1988) Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 89, 151-161, https://doi.org/10.1007/BF00489918
42. Girardi, A.C., Degray, B.C., Nagy, T., Biemesderfer, D. and Aronson, P.S. (2001) Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J. Biol. Chem. 276, 46671-46677, https://doi.org/10.1074/jbc.M106897200
43. Girardi, A.C., Knauf, F., Demuth, H.U. and Aronson, P.S. (2004) Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am. J. Physiol. Cell Physiol. 287, C1238-C1245, https://doi.org/10.1152/ajpcell.00186.2004
44. Tiruppathi, C., Miyamoto, Y., Ganapathy, V., Roesel, R.A., Whitford, G.M. and Leibach, F.H. (1990) Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J. Biol. Chem. 265, 1476-1483
45. Jackson, E.K., Kochanek, S.J. and Gillespie, D.G. (2012) Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 60, 757-764, https://doi.org/10.1161/HYPERTENSIONAHA.112.196501
46. Yang, J., Campitelli, J., Hu, G., Lin, Y., Luo, J. and Xue, C. (2007) Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci. 81, 272-279, https://doi.org/10.1016/j.lfs.2007.04.040
47. Chen, Y.T., Wallace, C.G., Yang, C.C., Chen, C.H., Chen, K.H., Sung, P.H. et al. (2017) DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning. Oncotarget 8, 54821-54837
48. Elleder, M. and Stejskal, J. (1985) Induction of dipeptidylpeptidase IV activity in human renal glomeruli-a histochemical study. Acta Histochem. 77, 75-78, https://doi.org/10.1016/S0065-1281(85)80019-2
49. Stiller, D., Bahn, H. and August, C. (1991) Demonstration of glomerular DPP IV activity in kidney diseases. Acta Histochem. 91, 105-109, https://doi.org/10.1016/S0065-1281(11)80302-8
50. Sharkovska, Y., Reichetzeder, C., Alter, M., Tsuprykov, O., Bachmann, S., Secher, T. et al. (2014) Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 32, 2211-2223, https://doi.org/10.1097/HJH.0000000000000328
51. Stefanovic, V., Ardaillou, N., Vlahovic, P., Placier, S., Ronco, P. and Ardaillou, R. (1993) Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 80, 465-470
52. Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L. et al. (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem. Biophys. Res. Commun. 310, 28-31, https://doi.org/10.1016/j.bbrc.2003.08.111
53. Stange, T., Kettmann, U. and Holzhausen, H.J. (2000) Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur. J. Histochem. 44, 157-164
54. Stange, T., Kettmann, U. and Holzhausen, H.J. (1996) Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Acta Histochem. 98, 323-331, https://doi.org/10.1016/S0065-1281(96)80025-0
55. Mitic, B., Lazarevic, G., Vlahovic, P., Rajic, M. and Stefanovic, V. (2008) Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren. Fail. 30, 896-903, https://doi.org/10.1080/08860220802359048
56. Sun, A.L., Deng, J.T., Guan, G.J., Chen, S.H., Liu, Y.T., Cheng, J. et al. (2012) Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab. Vasc. Dis. Res. 9, 301-308, https://doi.org/10.1177/1479164111434318
57. Wolke, C., Teumer, A., Endlich, K., Endlich, N., Rettig, R., Stracke, S. et al. (2017) Serum protease activity in chronic kidney disease patients: The GANI MED renal cohort. Exp. Biol. Med. (Maywood) 242, 554-563, https://doi.org/10.1177/1535370216684040
58. Zheng, T., Baskota, A., Gao, Y., Tian, H. and Yang, F. (2015) Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. Nephrol. Dial. Transplant. 30, 460-466, https://doi.org/10.1093/ndt/gfu312
59. Zheng, T., Liu, Y., Qin, S., Liu, H., Zhang, X. and Zhao, H. (2016) Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study. Diab. Vasc. Dis. Res. 13, 127-136, https://doi.org/10.1177/1479164115615356
60. Duvnjak, L., Perkovic, M.N. and Blaslov, K. (2017) Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes. J. Diabetes Complications 31, 218-222, https://doi.org/10.1016/j.jdiacomp.2016.08.022
61. Alter, M.L., Ott, I.M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K. et al. (2012) DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press. Res. 36, 119-130, https://doi.org/10.1159/000341487
62. Nakashima, S., Matsui, T., Takeuchi, M. and Yamagishi, S.I. (2014) Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm. Metab. Res. 46, 717-721, https://doi.org/10.1055/s-0034-1371892
63. Matsui, T., Nakashima, S., Nishino, Y., Ojima, A., Nakamura, N., Arima, K. et al. (2015) Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab. Invest. 95, 525-533, https://doi.org/10.1038/labinvest.2015.35
64. Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y. et al. (2014) Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63, 2120-2131, https://doi.org/10.2337/db13-1029
65. Shi, S., Srivastava, S.P., Kanasaki, M., He, J., Kitada, M., Nagai, T. et al. (2015) Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int. 88, 479-489, https://doi.org/10.1038/ki.2015.103
66. Takashima, S., Fujita, H., Fujishima, H., Shimizu, T., Sato, T., Morii, T. et al. (2016) Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 90, 783-796, https://doi.org/10.1016/j.kint.2016.06.012
67. Gill, A., Gray, S.P., Watson, A.M.D., Cooper, M.E. and Jandeleit-Dahm, K. A.M. (2017) Renoprotective effects of linagliptin and empagliflozin in a rat model of early diabetic nephropathy. Diabetes 66, A130 (492-P)
68. Chaykovska, L., Alter, M.L., von Websky, K., Hohmann, M., Tsuprykov, O., Reichetzeder, C. et al. (2013) Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J. Hypertens. 31, 2290-2298, https://doi.org/10.1097/HJH.0b013e3283649b4d
69. Nistala, R., Habibi, J., Aroor, A., Sowers, J.R., Hayden, M.R., Meuth, A. et al. (2014) DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity 22, 2172-2179, https://doi.org/10.1002/oby.20833
70. Tsuprykov, O., Ando, R., Reichetzeder, C., von Websky, K., Antonenko, V., Sharkovska, Y. et al. (2016) The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 89, 1049-1061, https://doi.org/10.1016/j.kint.2016.01.016
71. Tanaka, Y., Kume, S., Chin-Kanasaki, M., Araki, H., Araki, S.I., Ugi, S. et al. (2016) Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury. Biochem. Biophys. Res. Commun. 470, 539-545, https://doi.org/10.1016/j.bbrc.2016.01.109
72. Hasan, A.A., Reichetzeder, C., Guo, J., von Websky, K., Tsuprykov, O., Klein, T. et al. (2016) GLP-1 receptor independent effects of DPP-4 inhibition in mice with 5/6 nephrectomy. Diabetes 65, A132
73. Hasan, A.A. and Hocher, B. (2017) Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J. Mol. Endocrinol. 59, R1-R10, https://doi.org/10.1530/JME-17-0005
74. Kanasaki, K., Kitada, M. and Koya, D. (2012) Pathophysiology of the aging kidney and therapeutic interventions. Hypertens. Res. 35, 1121-1128, https://doi.org/10.1038/hr.2012.159
75. Schainuck, L.I., Striker, G.E., Cutler, R.E. and Benditt, E.P. (1970) Structural-functional correlations in renal disease. II. The correlations. Hum. Pathol. 1, 631-641, https://doi.org/10.1016/S0046-8177(70)80061-2
76. Striker, G.E., Schainuck, L.I., Cutler, R.E. and Benditt, E.P. (1970) Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum. Pathol. 1, 615-630, https://doi.org/10.1016/S0046-8177(70)80060-0
77. Risdon, R.A., Sloper, J.C. and De Wardener, H.E. (1968) Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2, 363-366, https://doi.org/10.1016/S0140-6736(68)90589-8
78. Nath, K.A. (1992) Tubulointerstitial changes as a major determinant in the progression of renal damage. Am. J. Kidney Dis. 20, 1-17, https://doi.org/10.1016/S0272-6386(12)80312-X
79. Mackensen-Haen, S., Bader, R., Grund, K.E. and Bohle, A. (1981) Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin. Nephrol. 15, 167-171
80. Zhang, L.H., Pang, X.F., Bai, F., Wang, N.P., Shah, A.I., McKallip, R.J. et al. (2015) Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart. Cardiovasc. Drugs Ther. 29, 243-255, https://doi.org/10.1007/s10557-015-6592-7
81. Hirakawa, H., Zempo, H., Ogawa, M., Watanabe, R., Suzuki, J., Akazawa, H. et al. (2015) A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PLoS ONE 10, e0119360, https://doi.org/10.1371/journal.pone.0119360
82. Koibuchi, N., Hasegawa, Y., Katayama, T., Toyama, K., Uekawa, K., Sueta, D. et al. (2014) DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc. Diabetol. 13, 157, https://doi.org/10.1186/s12933-014-0157-0
83. Aroor, A.R., Habibi, J., Kandikattu, H.K., Garro-Kacher, M., Barron, B., Chen, D. et al. (2017) Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovasc. Diabetol. 16, 61, https://doi.org/10.1186/s12933-017-0544-4
84. Manrique, C., Habibi, J., Aroor, A.R., Sowers, J.R., Jia, G., Hayden, M.R. et al. (2016) Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc. Diabetol. 15, 94, https://doi.org/10.1186/s12933-016-0414-5
85. Nagai, T., Doi, S., Nakashima, A., Irifuku, T., Sasaki, K., Ueno, T. et al. (2016) Linagliptin ameliorates methylglyoxal-induced peritoneal fibrosis in mice. PLoS ONE 11, e0160993, https://doi.org/10.1371/journal.pone.0160993
86. Zeisberg, E.M., Potenta, S.E., Sugimoto, H., Zeisberg, M. and Kalluri, R. (2008) Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287, https://doi.org/10.1681/ASN.2008050513
87. He, J., Xu, Y., Koya, D. and Kanasaki, K. (2013) Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin. Exp. Nephrol. 17, 488-497, https://doi.org/10.1007/s10157-013-0781-0
88. Li, J., Qu, X. and Bertram, J.F. (2009) Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 175, 1380-1388, https://doi.org/10.2353/ajpath.2009.090096
89. Kizu, A., Medici, D. and Kalluri, R. (2009) Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am. J. Pathol. 175, 1371-1373, https://doi.org/10.2353/ajpath.2009.090698
90. Strutz, F. and Zeisberg, M. (2006) Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 17, 2992-2998, https://doi.org/10.1681/ASN.2006050420
91. Piera-Velazquez, S., Mendoza, F.A. and Jimenez, S.A. (2016) Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. J. Clin. Med. 5, 45, https://doi.org/10.3390/jcm5040045
92. Piera-Velazquez, S., Li, Z. and Jimenez, S.A. (2011) Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 179, 1074-1080, https://doi.org/10.1016/j.ajpath.2011.06.001
93. Karasek, M.A. (2007) Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med. Hypotheses 68, 650-655, https://doi.org/10.1016/j.mehy.2006.07.053
94. Delic, D., Sontheimer, K., Tsuprykov, O., Hasan, A.A., Hocher, B., Baum, P. et al. (2017) Dipeptidyl peptidase inhibitor linagliptin-and angiotensin II receptor blocker telmisartan-induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy. Diabetes 66, A131 (496-P)
95. Chung, A.C. and Lan, H.Y. (2015) MicroRNAs in renal fibrosis. Front Physiol. 6, 50, https://doi.org/10.3389/fphys.2015.00050
96. Gomez, I.G., Nakagawa, N. and Duffield, J.S. (2016) MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis. Am. J. Physiol. Renal Physiol. 310, F931-F944, https://doi.org/10.1152/ajprenal.00523.2015
97. Srivastava, S.P., Koya, D. and Kanasaki, K. (2013) MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. Biomed. Res. Int. 2013, 125469, https://doi.org/10.1155/2013/125469
98. Chen, P.Y., Qin, L., Barnes, C., Charisse, K., Yi, T., Zhang, X. et al. (2012) FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2, 1684-1696, https://doi.org/10.1016/j.celrep.2012.10.021
99. Nagai, T., Kanasaki, M., Srivastava, S.P., Nakamura, Y., Ishigaki, Y., Kitada, M. et al. (2014) N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed. Res. Int. 2014, 696475, https://doi.org/10.1155/2014/696475
100. Srivastava, S.P., Shi, S., Kanasaki, M., Nagai, T., Kitada, M., He, J. et al. (2016) Effect of antifibrotic microRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis. Sci. Rep. 6, 29884, https://doi.org/10.1038/srep29884
101. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687, https://doi.org/10.1016/S0092-8674(02)00971-6
102. Liu, S., Kapoor, M., Denton, C.P., Abraham, D.J. and Leask, A. (2009) Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum. 60, 2817-2821, https://doi.org/10.1002/art.24801
103. Yeh, Y.C., Wei, W.C., Wang, Y.K., Lin, S.C., Sung, J.M. and Tang, M.J. (2010) Transforming growth factor-(beta)1 induces Smad3-dependent (beta)1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. Am. J. Pathol. 177, 1743-1754, https://doi.org/10.2353/ajpath.2010.091183
104. Hamzeh, M.T., Sridhara, R. and Alexander, L.D. (2015) Cyclic stretch-induced TGF-beta1 and fibronectin expression is mediated by beta1-integrin through c-Src-and STAT3-dependent pathways in renal epithelial cells. Am. J. Physiol. Renal Physiol. 308, F425-F436, https://doi.org/10.1152/ajprenal.00589.2014
105. Sato, T., Yamochi, T., Aytac, U., Ohnuma, K., McKee, K.S., Morimoto, C. et al. (2005) CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 65, 6950-6956, https://doi.org/10.1158/0008-5472.CAN-05-0647
106. Medici, D., Shore, E.M., Lounev, V.Y., Kaplan, F.S., Kalluri, R. and Olsen, B.R. (2010) Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406, https://doi.org/10.1038/nm.2252
107. Zeisberg, M. and Zeisberg, E.M. (2015) Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int. 88, 429-431, https://doi.org/10.1038/ki.2015.175
108. Kanasaki, K. (2016) The pathological significance of dipeptidyl peptidase-4 in endothelial cell homeostasis and kidney fibrosis. Diabetol. Int. 7, 212-220, https://doi.org/10.1007/s13340-016-0281-z
109. Liu, Y., Taylor, N.E., Lu, L., Usa, K., Cowley, Jr, A.W., Ferreri, N.R. et al. (2010) Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 55, 974-982, https://doi.org/10.1161/HYPERTENSIONAHA.109.144428
110. Wong, M.G., Panchapakesan, U., Qi, W., Silva, D.G., Chen, X.M. and Pollock, C.A. (2011) Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am. J. Physiol. Renal Physiol. 301, F84-F93, https://doi.org/10.1152/ajprenal.00287.2010
111. Panchapakesan, U., Gross, S., Komala, M.G., Pegg, K. and Pollock, C.A. (2013) DPP4 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? J. Diabetes Metab. S9, 007, https://doi.org/10.4172/2155-6156.S9-007
112. Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C. and Panchapakesan, U. (2015) Linagliptin limits high glucose induced conversion of latent to active TGFss through interaction with CIM6PR and limits renal tubulointerstitial fibronectin. PLoS ONE 10, e0141143, https://doi.org/10.1371/journal.pone.0141143
113. Forst, T., Michelson, G., Diessel, S., Jahnke, J. and Kapitza, C. (2016) Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. J. Hypertens. 34, 345-350, https://doi.org/10.1097/HJH.0000000000000776
114. Yamagishi, S., Nakamura, N., Suematsu, M., Kaseda, K. and Matsui, T. (2015) Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol. Med. 21, S32-S40, https://doi.org/10.2119/molmed.2015.00067
115. Ishibashi, Y., Matsui, T., Maeda, S., Higashimoto, Y. and Yamagishi, S. (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 12, 125, https://doi.org/10.1186/1475-2840-12-125
116. Yamagishi, S., Fukami, K. and Matsui, T. (2015) Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol. 14, 2, https://doi.org/10.1186/s12933-015-0176-5
117. Kroller-Schon, S., Knorr, M., Hausding, M., Oelze, M., Schuff, A., Schell, R. et al. (2012) Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 96, 140-149, https://doi.org/10.1093/cvr/cvs246
118. Yamagishi, S., Ishibashi, Y., Ojima, A., Sugiura, T. and Matsui, T. (2014) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int. J. Cardiol. 176, 550-552, https://doi.org/10.1016/j.ijcard.2014.07.023
119. Yang, Z., Spencer, N.Y. and Stanton, R.C. (2016) Linagliptin ameliorates kidney hypertrophy and albuminuria in diabetic mice in a glucose-independent manner via increased antioxidant function. Diabetes 65, A131-2 (504-P)
120. Vellecco, V., Mitidieri, E., Gargiulo, A., Brancaleone, V., Matassa, D., Klein, T. et al. (2016) Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway. Diabetes Obes. Metab. 18, 1236-1243, https://doi.org/10.1111/dom.12750
121. Salheen, S.M., Panchapakesan, U., Pollock, C.A. and Woodman, O.L. (2015) The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol. Res. 94, 26-33, https://doi.org/10.1016/j.phrs.2015.02.003
122. Stokman, G., Stroo, I., Claessen, N., Teske, G.J., Florquin, S. and Leemans, J.C. (2010) SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol. Dial. Transplant. 25, 3852-3859, https://doi.org/10.1093/ndt/gfq311
123. Togel, F., Isaac, J., Hu, Z., Weiss, K. and Westenfelder, C. (2005) Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int. 67, 1772-1784, https://doi.org/10.1111/j.1523-1755.2005.00275.x
124. Hocher, B., Sharkovska, Y., Mark, M., Klein, T. and Pfab, T. (2013) The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int. J. Cardiol. 167, 87-93, https://doi.org/10.1016/j.ijcard.2011.12.007
125. Fadini, G.P., Bonora, B.M., Cappellari, R., Menegazzo, L., Vedovato, M., Iori, E. et al. (2016) Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 748-756, https://doi.org/10.1210/jc.2015-3716
126. Lovshin, J.A., Rajasekeran, H., Lytvyn, Y., Lovblom, L.E., Khan, S., Alemu, R. et al. (2017) Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha1-67 in patients with type 2 diabetes. Diabetes Care 40, 1073-1081, https://doi.org/10.2337/dc17-0061
127. Papazafiropoulou, A.K., Papanas, N., Trikkalinou, A., Fousteris, E. and Melidonis, A. (2017) The oral dipeptidyl-peptidase-4 inhibitor sitagliptin increases circulating levels of stromal-derived factor-1 alpha. Exp. Clin. Endocrinol. Diabetes, https://doi.org/10.1055/s-0043-118748
128. Muskiet, M.H.A., Tonneijck, L., Smits, M.M., van Baar, M.J.B., Kramer, M.H.H., Hoorn, E.J. et al. (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605-628, https://doi.org/10.1038/nrneph.2017.123
129. Vallon, V. and Docherty, N.G. (2014) Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp. Physiol. 99, 1140-1145, https://doi.org/10.1113/expphysiol.2014.078766
130. Hocher, B., Reichetzeder, C. and Alter, M.L. (2012) Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press. Res. 36, 65-84, https://doi.org/10.1159/000339028
131. Chaykovska, L., von Websky, K., Rahnenfuhrer, J., Alter, M., Heiden, S., Fuchs, H. et al. (2011) Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE 6, e27861, https://doi.org/10.1371/journal.pone.0027861
132. Connelly, K.A., Bowskill, B.B., Advani, S.L., Thai, K., Chen, L.H., Kabir, M.G. et al. (2014) Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin. Invest. Med. 37, E172-E185, https://doi.org/10.25011/cim.v37i3.21384
133. Panchapakesan, U. and Pollock, C.A. (2014) DPP-4 inhibitors-renoprotection in diabetic nephropathy? Diabetes 63, 1829-1830, https://doi.org/10.2337/db14-0366
134. Schnapp, G., Klein, T., Hoevels, Y., Bakker, R.A. and Nar, H. (2016) Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure. J. Med. Chem. 59, 7466-7477, https://doi.org/10.1021/acs.jmedchem.6b00475
135. Fuchs, H., Binder, R. and Greischel, A. (2009) Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm. Drug Dispos. 30, 229-240, https://doi.org/10.1002/bdd.662
136. Greischel, A., Binder, R. and Baierl, J. (2010) The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time-and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats. Drug Metab. Dispos. 38, 1443-1448, https://doi.org/10.1124/dmd.110.034199
137. Thomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F. and Mark, M. (2008) (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325, 175-182, https://doi.org/10.1124/jpet.107.135723
138. Luippold, G., Klein, T., Mark, M., Amann, K. and Daniel, C. (2017) The binding kinetics of linagliptin uniquely mediate its kidney-specific DPP-4 inhibition. Diabetes 66, A14 (54-OR)
139. Takai, S., Sakonjo, H. and Jin, D. (2014) Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J. Pharmacol. Sci. 125, 386-393, https://doi.org/10.1254/jphs.14052FP
140. Shi, S., Kanasaki, K. and Koya, D. (2016) Linagliptin but not sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 471, 184-190, https://doi.org/10.1016/j.bbrc.2016.01.154
141. Reichetzeder, C., von Websky, K., Tsuprykov, O., Mohagheghi Samarin, A., Falke, L.G., Dwi Putra, S.E. et al. (2017) Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. Br. J. Pharmacol. 174, 2273-2286, https://doi.org/10.1111/bph.13822
142. Mosenzon, O., Leibowitz, G., Bhatt, D.L., Cahn, A., Hirshberg, B., Wei, C. et al. (2017) Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40, 69-76, https://doi.org/10.2337/dc16-0621
143. Cornel, J.H., Bakris, G.L., Stevens, S.R., Alvarsson, M., Bax, W.A., Chuang, L.M. et al. (2016) Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39, 2304-2310, https://doi.org/10.2337/dc16-1415
144. Mann, J.F.E., Orsted, D.D., Brown-Frandsen, K., Marso, S.P., Poulter, N.R., Rasmussen, S. et al. (2017) Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839-848, https://doi.org/10.1056/NEJMoa1616011
145. Tonneijck, L., Smits, M.M., Muskiet, M.H., Hoekstra, T., Kramer, M.H., Danser, A.H. et al. (2016) Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39, 2042-2050, https://doi.org/10.2337/dc16-1371
146. Chao, C.T., Wang, J., Wu, H.Y., Chien, K.L. and Hung, K.Y. (2017) Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget 8, 53028-53040, https://doi.org/10.18632/oncotarget.18081
147. Laakso, M., Rosenstock, J., Groop, P.H., Barnett, A.H., Gallwitz, B., Hehnke, U. et al. (2015) Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care 38, e15-e17, https://doi.org/10.2337/dc14-1684
148. McGill, J.B., Sloan, L., Newman, J., Patel, S., Sauce, C., von Eynatten, M. et al. (2013) Long-term efficacy and safety of linagliptin in patients with type 2. diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 36, 237-244, https://doi.org/10.2337/dc12-0706
149. von Eynatten, M., Gong, Y., Emser, A. and Woerle, H.J. (2013) Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc. Diabetol. 12, 60, https://doi.org/10.1186/1475-2840-12-60
150. Groop, P.H., Cooper, M.E., Perkovic, V., Emser, A., Woerle, H.J. and von Eynatten, M. (2013) Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36, 3460-3468, https://doi.org/10.2337/dc13-0323
151. Cooper, M.E., Perkovic, V., McGill, J.B., Groop, P.H., Wanner, C., Rosenstock, J. et al. (2015) Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am. J. Kidney Dis. 66, 441-449, https://doi.org/10.1053/j.ajkd.2015.03.024
152. Groop, P.H., Cooper, M.E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M. et al. (2017) Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes. Metab. 19, 1610-1619, https://doi.org/10.1111/dom.13041
153. Ott, C., Kistner, I., Keller, M., Friedrich, S., Willam, C., Bramlage, P. et al. (2016) Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia 59, 2579-2587, https://doi.org/10.1007/s00125-016-4083-4
154. Veelken, R., Hilgers, K.F., Hartner, A., Haas, A., Bohmer, K.P. and Sterzel, R.B. (2000) Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 11, 71-79
155. Schlaich, M.P., Schmitt, D., Ott, C., Schmidt, B.M. and Schmieder, R.E. (2008) Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J. Hypertens. 26, 110-116, https://doi.org/10.1097/HJH.0b013e3282f1a93e
156. Jax, T., Stirban, A., Terjung, A., Esmaeili, H., Berk, A., Thiemann, S. et al. (2017) A randomised, active-and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro-and microvascular endothelial function in type 2 diabetes. Cardiovasc. Diabetol. 16, 13, https://doi.org/10.1186/s12933-016-0493-3
157. Hocher, B. and Adamski, J. (2017) Metabolomics for clinical use and research in chronic kidney disease. Nat. Rev. Nephrol. 13, 269-284, https://doi.org/10.1038/nrneph.2017.30
158. Rosenstock, J., Perkovic, V., Alexander, J.H., Cooper, M.E., Kahn, S.E., Marx, N. et al. (2017) CARMELINA R+ trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk. Diabetes 66, A344 (1284-P)